Aspirin May Prevent Melanoma in Postmenopausal White Women.


Regular aspirin use is associated with a reduction in melanoma risk among postmenopausal white women, according to an analysis from the Women’s Health Initiative Observational Study, published in Cancer.

Researchers followed nearly 60,000 women for a median of 12 years. During that time, some 550 melanomas were diagnosed. Women who reported using aspirin regularly had a 21% lower incidence of melanoma than those taking nonaspirin NSAIDs or those not taking NSAIDs.

In Journal Watch Dermatology, Jeffrey P. Callen writes: “Unless there is a contraindication, I will tell a patient who asks my advice that low-dose aspirin seems to usefully reduce melanoma risk.”

Source: Journal Watch Dermatology summary

Why greeting cards aren’t dead.


 

alexahirschfeld

When guests visited the Hirschfeld family’s Manhattan home in the early nineties, Alexa Hirschfeld played gallery owner.

The towheaded elementary schooler would run upstairs to her younger brother James’s closet, then return with handfuls of his artwork. She’d dazzle guests with his latest paintings and sketches, pointing out aspects of each work she knew each visitor would find most compelling. Hirschfeld took care to remember who liked which piece best, and which styles of her brother’s art earned the most attention.

“I never knew what my role in art was,” she reflects. “Because I was such a deep appreciator, and such passionate appreciator. But every time I would try to sit down and be an illustrator or painter, it was just not my best use.”

Nearly two decades later, she is still helping others appreciate art, albeit in a much different medium. We’re sitting at a conference table at her and James’s online card company, Paperless Post, in the Chelsea neighborhood of Manhattan. Hirschfeld looks more than a little tired, slumped into a bright red chair in the otherwise white room. I’ve pulled her away from talks with her Web developer team over a new iPad app.

“Busy day?” I ask. “Every day is busy,” she sighs. It’s less a complaint than an acknowledgment of reality — she’s the 28-year-old cofounder of a startup that’s gained 2 million users over its three years of existence.

The Hirschfeld siblings launched Paperless Post in 2009 based on the idea that people actually want visually pleasing online content. James, then a college senior, felt the Internet lacked artful options for invitations and greeting cards. So he posed the concept of creating a digital card company to Alexa.

“The first thing I said was that people would use it, and I don’t know if they’d pay for it,” she remembers telling her brother. So the siblings researched the approaches of likely competitors, services such as Evite and Facebook Events.

“We looked so closely at all of them. And instead of being disturbed by what we saw, it really helped us narrow our entry point to the market,” Alexa tells me. She speaks slowly and deliberately, looking off at the side wall as she formulates her response. “We basically positioned ourselves as something super narrow and super new — a more design-focused company, which was seeking to bring the best of the old tradition to the new medium, and updating it to make it better where possible.”

The Hirschfelds took care to study what users wanted from online greetings and invitations. People seemed to view the current offerings as wanting in terms of style.

“I thought it was interesting that none of the competitors online really cared about the invitation itself, they all cared about the Web presence. It was like an afterthought. Whereas all the users in the real world really cared about the invitation itself. That was probably the most surprising thing, it was the most heartening thing too. What the consumer wants is, surprise surprise,” she smiles, “pretty things, easy things, responsive things.”

So, Alexa and her brother created a business plan that might seem archaically sensible in the current tech age. “We basically built a pricing model that surgically identified what people wanted to pay us for and what they didn’t want to pay us for,” she explains. “One of the things we figured out early on was that we could create value for people by creating a product that allowed them to design something that they couldn’t design without us.”

Paperless Post began as a fully premium service, with a set price for every card. But the Hirschfelds soon learned that users preferred to pay per card feature. The site now operates on a coin system, with each coin costing about 20 cents. Those coins buy customizable features for your card, such as envelope liners, stamps, additional notes, and different colored backgrounds. Paperless Post cards feature in-house illustrations, as well as graphics made through partnerships with designers like Kate Spade. Sending multiple cards multiplies the number of coins that a particular greeting costs. Some simple, non-customized cards can be sent for free, and new users begin with 25 coins in their digital purse.

Those small coin payments have added up for the startup. It reached a positive cash flow by its second year of business. Paperless Post also has managed to penetrate a market that has evaded its less design-conscious competitors — digital wedding invitations.

Hirschfeld credits the startup’s success to a practical harnessing of aesthetics. “I believe in form,” she tells me, looking off at the wall again, “and the manner of what you say being as important as the content of what you say. And what this company lets people do is in line with that. ”

As a classics major at Harvard University, Alexa wrote her thesis about the poet Constantine Cavafy, which provides some insight into her philosophy about design. “His entire poetics was about the importance of style. A lot of time the style is the substance.” And with Paperless Post, she says, appearance really is the product.

While the company originally found success offering the digital version of something physical, it recently began offering paper versions of its digital cards.

“So many people were asking for it,” Hirschfeld says of the printed product line, “it would have been a risk not to build it and try it.”

So Paperless Post launched its Paper line in October 2012, at a price point five to 10 times higher than its digital cards. Within five weeks of launch, the founders witnessed a day when Paper’s revenue outstripped that of the digital cards.

I ask Hirschfeld whether the success of paper cards spells failure for digital greetings. “No,” she answers with certainty. “It’s that,” she pauses, “basically print is more of a statement now. People still want to make those statements.” She says there are uniquely physical ways in which one uses paper greetings, such as the holiday cards you find displayed on the mantle or the name cards at a wedding reception table. “The physical world is not going away,” she adds, “just items take on different meaning. Paper takes on this archival, very important meaning now that it’s not the only way to communicate something.”

Hirschfeld sees this dual online-offline access as key to a modern content company’s success. She points to Netflix and Amazon (with its Kindle) as companies that have made a flexible medium the product itself — we pay them for the way they allow us to easily access content.

“Seamlessness makes a lot of sense for us,” she explains. “Because even hard paper invitations are a digital product. The physical item itself is not always the most important part, it’s the visual information and the actual data that’s important. A design is an intellectual product.”

Two decades after her years as a child curator, Hirschfeld has found her role in the creative world– connecting people with aesthetics for which they’re happy to pay.

Source: Smart Planet.

FDA Admits Chicken Meat Contains Arsenic.


 

chicken-300x169

Killing animals for mass consumption is inhumane and not harmonious with our hearts. We have been desensitized to inhumane practices within the food industry. It’s been over 6 years since The Institute for Agriculture and Trade Policy (IATP) found that chicken contained Arsenic. With the risk of being exposed, the FDA has finally admitted to this fact and no longer can they continue with their desire to sweep this information under the rug.

Ingested inorganic arsenic is metabolized to mono and dimethylated compounds, these are predominantly found in urine. Big pharmaceutical companies produce and sell four arsenic compounds that are added to animal feed for turkey, chicken and swine production to increase weight and improve pigmentation of the meat. As far back as 2006, the IATP’s report Playing Chicken: Avoiding Arsenic in your meat estimated that more than 70 percent of all U.S. chickens raised for meat are fed arsenic. That report found detectable levels of arsenic in many  brand name poultry products form supermarkets and fast food restaurants. One way farmers add arsenic to chicken feed is through drugs like Pfizer’s Roxarsone.

Arsenic’s a poison that causes cancer, among other harm. The FDA can’t seriously uphold its public health mission while allowing residues of arsenic in the meat our children and families eat. – David Wallinga, M.D. IATP

It’s about time that the FDA took action, they have confirmed that chickens given the drug do test positive for inorganic arsenic which, as stated above was found as early as 2006. Despite finding this fact in 2006, the industry continued to ignore it and steadily maintained that arsenic could not and did not make it into the meat. While admitting to the arsenic, the FDA continues to maintain that there is no meaningful risk to those eating the chicken. It is no surprise that this point is emphasized by the pharmaceutical company and the National Chicken Council. How can the FDA claim that arsenic at a low level is still safe to eat? How can we be sure it is at a low level given how cancer rates are rising every year? Even though the FDA admits to arsenic being a carcinogen, meaning it increases the risk of cancer, they still justify its placement in the chicken we eat. Chicken littler containing arsenic is also fed to cows in factory beef operations. So the arsenic that’s pooped out by the chickens gets consumed and concentrated in the tissues of cows, which is then ground into hamburger to be consumed by the masses who don’t even know they’re eating it.

Human health affects of arsenic exposure, especially inorganic arsenic exposure, can vary depending on route of exposure. For ingestion, adverse effects are most often manifested as skin discolouration and lesions and in the gastrointestinal tract (nausea, diarrhoea, and abdominal pain). Ingestion has also been linked to cancer of the skin, bladder, liver and lung. Inhalation exposure has been linked to an increased incidence of irritation of mucous membranes and lung cancer. Inorganic arsenic is classified as a known human carcinogen.

The state of Maryland has recently passed a bill that bans arsenic in chicken feed. Pfizer’s roxarsone arsenic based drug has been in chicken feed since the 1940′s. The inorganic arsenic not only ends up in meat, it ends up in soil. The chickens in Maryland, for example, produce about a billion pounds of waste a year and that waste gets used as fertilizer. Maryland is the first state to pass such a bill, and it is logical to assume that this problem exists with chicken feed, the chicken meat and the fertilizer from chicken waste in all other states too. It’s good to know that this is becoming known, and I am sure this information will spread as we continue to wake up.

 

Sources:

http://www.epa.gov/teach/chem_summ/Arsenic_summary.pdf

http://www.mnn.com/food/healthy-eating/blogs/arsenic-in-chicken-feed-affects-more-than-chickens

http://www.iatp.org/blog/201112/arsenic—it’s-in-animal-feed-too

http://grist.org/food-safety/2011-06-08-fda-admits-supermarket-chickens-test-positive-for-arsenic/

http://worldtruth.tv/fda-finally-admits-chicken-meat-contains-cancer-causing-arsenic/

http://www.huffingtonpost.com/2011/06/08/arsenic-chicken_n_873299.html

Outbreak of Shigellosis Showed Decreased Susceptibility to Azithromycin.


 

An outbreak of shigellosis that occurred in Los Angeles last year is the first known transmission in the U.S. of Shigella sonnei with resistance to azithromycin, according to MMWR.

Of 43 cases of shigellosis associated with a private bridge club, 14 were confirmed by culture. Four isolates had elevated azithromycin minimum inhibitory concentrations (MICs) of >16 μg/mL and a plasmid-encoded macrolide resistance gene.

The authors write: “Guidelines for azithromycin susceptibility testing and criteria for interpretation of MICs for Shigella species have not been published. Clinicians are urged to report azithromycin treatment failure among shigellosis patients to public health authorities and to retain Shigella isolates from such cases for further analysis.”

Source: MMWR

Researchers assess 48-hour effects of cinacalcet in patients with secondary hyperparathyroidism.


 

The association between patients on hemodialysis with elevated parathyroid hormone, serum calcium, phosphorus levels, and the development of vascular calcifications has been established. However, in this patient population with secondary hyperparathyroidism controlled by cinacalcet (Sensipar, Amgen), researchers have found a transient reduction in parathyroid hormone and phosphorus, and an increase in calcitonin following each dose, further suggesting that the discontinuation of cinacalcet induces a significant increase of parathyroid hormone.

Researchers from the Hospital Perpetuo Socorro in Alicante, Spain, conducted a phase 4, open-label, single arm, single dose, clinical trial. Ten patients on cinacalcet for 6 months or longer with intact parathyroid hormone (PTH) levels of 100 pg/mL to 400 pg/mL were administered 30 mg (n=6), 60 mg (n=3) or 90 mg (n=1) of the drug.

According to data, patients displayed a significant reduction in intact PTH between 1 and 6 hours, and values returned to baseline at 24 hours (maximum mean percentage change from baseline: –50%; 95% CI, –34% to –66% at 3 hours). Researchers also observed a transient increase in calcitonin and a decrease in phosphorus, with no changes to calcium levels, they wrote.

Additionally, researchers reported a significant increase in intact PTH (51%; 95% CI, 26-76) and phosphorus at 48 hours. They determined that changes to PTH were similar with the three determination methods (intact PTH, Scantibodies Laboratory; iPTH, Roche Diagnostics; PTH 1-84, Scantibodies Laboratory).

These findings suggest that blood samples taken at 12 and 24 hours after the last dose of cinacalcet provide reliable information on the overall degree of PTH control over the 24-hour dosing period. Furthermore, the assay used to measure PTH does not influence relative changes induced by cinacalcet, the researchers wrote.

Source: Endocrine Today.

Papillary thyroid carcinoma linked to Hashimoto’s thyroiditis.


 

Data from a recent meta-analysis demonstrate that papillary thyroid cancer is significantly associated with pathologically confirmed Hashimoto’s thyroiditis, despite decades of controversy.

Researchers from Korea University Ansan Hospital used citation databases to search the literature for relevant studies; they found 38 eligible studies that included 10,648 patients with papillary thyroid carcinoma (PTC). Of those, 23.2% had histologically proven Hashimoto’s thyroiditis.

According to the analysis, Compared with benign thyroid diseases and other carcinomas, Hashimoto’s thyroiditis was more commonly seen in PTC (OR=2.4 vs. 2.8; P<.001).

Additionally, cases of PTC with existing Hashimoto’s thyroiditis were significantly linked to female patients (OR=2.7; P<.001); multifocal involvement (OR=1.5; P=.010); no extrathyroidal extension (OR=1.3; P=.002); and no lymph node metastasis (OR=1.3; P=.041), the researchers wrote. The long recurrence-free survival among patients with both PTC and Hashimoto’s thyroiditis also was significant (HR=0.6; P=.001).

“Our meta-analysis showed that PTC is significantly associated with pathologically confirmed [Hashimoto’s thyroiditis]. PTC patients with [Hashimoto’s thyroiditis] have favorable clinicopathologic characteristics compared with PTCs without [Hashimoto’s thyroiditis]. However, patients with [Hashimoto’s thyroiditis] need to be carefully monitored for the development of PTC,” they wrote.

Source: Endocrine Today.

How to Eat Better and Fight Cancer with Your Fork.


Good nutrition is essential for maintaining a healthy weight and lifestyle and, according to Dana-Farber Nutritionist Stacy Kennedy, MPH, RD, CSO, LDN, it can also help in the battle against cancer.

“Good nutrition is really important for supporting a healthy immune system, which helps the healing process, and healthy eating can even help to alleviate side effects or symptoms related to cancer and treatment, such as fatigue, constipation, nausea, and mouth sores,” Kennedy says.

 

So where should the nutrition novice begin? The produce section. “Maintaining a healthy diet that is rich in plant-based foods is one way to not only promote survivorship, but also help to prevent cancer – it really is an excellent choice for everyone,” Kennedy says. She offers up these tips.

  1. Reach for bright colors. Look for brightly colored, in-season, preferably local, fruits and vegetables. What gives a fruit or vegetable its bright color, are specific phytonutrients, which are extremely beneficial for our immune systems.
  2. Be mindful of meat. A healthy diet can include protein-rich foods, like meat or fish. Just be mindful of the quality, type, and portion size.  Don’t forget to reach for protein-rich plants too, like lentils, beans, nuts, seeds, whole grains, and dark green, leafy vegetables.
  3. Keep certain foods off your plate. Reduce and limit your intake of sugary or processed foods, artificial ingredients (sweeteners, colors, preservatives, etc.), and fatty red meat; grass fed beef is healthy in moderation.
  4. Start small. If you are not ready to overhaul your diet, start with little steps. If you are eating a sandwich, add a tomato, avocado, or cucumber. Or grab an apple as a snack instead of a bag of chips. Even a slight increase in your fruit and vegetable intake can have lasting benefits.
  5. Ask an Expert. There’s often conflicting information in the media about nutrition and its role in treatment. Work with someone who can help you take in all of the information and create a plan that is right for you.
  • professional nutrition experts

 “I do love this app,” says Susan Gimilaro, a Dana-Farber patient who was diagnosed with multiple myeloma in March 2011. “First, the recipes are delicious.  And I like the shopping list; just click on a recipe, press the shopping list, and voila – I’ve got a grocery list!  The steps, nutrition info, and tips included in each recipe leave me without questions.”

But when Gimilaro does have questions, she knows where to turn. I was looking for information about chia seeds.  I found a variety of information on the Internet, but could I trust these sources?  I wasn’t sure,” Gimilaro says. “However, in this app, under the Ask the Nutritionists feature, there was information on chia seeds – from a source I can trust.”

“I feel that I am eating healthier because the app is so readily available and offers delicious recipes,” Gimilaro says. “It is just easy to use – there is really no learning curve.”

Source: Dana-Farber Cancer Institute.

 

Skin cancer ‘able to fight off body’s immune system’.


_66152233_melanoma_skin_cancer

·          

A deadly form of skin cancer is able to fend off the body’s immune system, UK researchers have found.

Analysis of tumour and blood samples shows that melanoma knocks out the body’s best immune defence.

A potential test could work out which patients are likely to respond to treatment, the Journal of Clinical Investigation reports.

Cancer Research UK said the body’s response was a “complex puzzle”.

Previous work from the team at King’s College London showed that while patients with melanoma produced antibodies that could attack tumour cells, the immune system often seemed powerless to stop the cancer progressing.

But in the latest research they discovered that the subtype of antibody attracted by the melanoma cells was the most ineffective at mounting the right sort of response.

In samples from 80 melanoma patients they say that the conditions created by the tumour attract IgG4 antibodies, which mount the weakest response and in turn interfere with any “strong” IgG1 antibodies that might be present.

By mimicking the conditions created by melanomas, they showed that in the presence of tumour cells, the immune system sent out IgG4 antibodies, but when faced with healthy cells it functioned as expected with IgG1 circulating.

They also confirmed that IgG4 was ineffective in launching an immune attack against cancer cells.

Potential test

In additional tests in 33 patients, they found that those with higher levels of the weak antibody IgG4 had a less favourable prognosis compared with those with levels nearer to normal.

Study author Dr Sophie Karagiannis said: “This work bears important implications for future therapies since not only are IgG4 antibodies ineffective in activating immune cells to kill tumours but they also work by blocking antibodies from killing tumour cells.”

She said not only was IgG4 stopping the patient’s more powerful antibodies from eradicating cancer, but it could also explain why some treatments based on boosting the immune response may be less effective in some patients.

Co-author Prof Frank Nestle said more work was needed on developing IgG4 as a potential test to improve patient care by helping to identify patients most likely to respond to treatments.

“This study can also inform the rational design of novel strategies to counteract IgG4 actions,” he added.

Dr Kat Arney, science communications manager at Cancer Research UK, said: “There’s a lot we don’t yet understand about how our immune system recognises and responds to cancer, so we’re pleased to have supported this new research that’s helping to solve such a complex puzzle.

“This work is still at an early stage, but it’s a step towards developing more effective treatments for skin cancer and potentially other types of cancer in the future.”

Source: BBC

US HIV baby ‘cured’ by early drug treatment.


A baby girl in the US born with HIV appears to have been cured after very early treatment with standard drug therapy, doctors say.

The Mississippi child is now two-and-a-half years old and has been off medication for about a year with no signs of infection.

More testing needs to be done to see if the treatment – given within hours of birth – would work for others.

If the girl stays healthy, it would be the world’s second reported ‘cure’.

Dr Deborah Persaud, a virologist at Johns Hopkins University in Baltimore, presented the findings at the Conference on Retroviruses and Opportunistic Infections in Atlanta.

“This is a proof of concept that HIV can be potentially curable in infants,” she said.

Cocktail of drugs

In 2007, Timothy Ray Brown became the first person in the world believed to have recovered from HIV.

His infection was eradicated through an elaborate treatment for leukaemia that involved the destruction of his immune system and a stem cell transplant from a donor with a rare genetic mutation that resists HIV infection.

In contrast, the case of the Mississippi baby involved a cocktail of widely available drugs, known as antiretroviral therapy, already used to treat HIV infection in infants.

It suggests the swift treatment wiped out HIV before it could form hideouts in the body.

These so-called reservoirs of dormant cells usually rapidly reinfect anyone who stops medication, said Dr Persaud.

The baby was born in a rural hospital where the mother had only just tested positive for HIV infection.

Because the mother had not been given any prenatal HIV treatment, doctors knew the baby was at high risk of being infected.

Researchers said the baby was then transferred to the University of Mississippi Medical Center in Jackson.

Once there, paediatric HIV specialist Dr Hannah Gay put the infant on a cocktail of three standard HIV-fighting drugs at just 30 hours old, even before laboratory tests came back confirming the infection.

“I just felt like this baby was at higher-than-normal risk and deserved our best shot,” Dr Gay said.

The treatment was continued for 18 months, at which point the child disappeared from the medical system. Five months later the mother and child turned up again but had stopped the treatment in this interim.

The doctors carried out tests to see if the virus had returned and were astonished to find that it had not.

Dr Rowena Johnston, of the Foundation for Aids Research, said it appeared that the early intervention that started immediately after birth worked.

“I actually do believe this is very exciting.

“This certainly is the first documented case that we can truly believe from all the testing that has been done.

“Many doctors in six different laboratories all applied different, very sophisticated tests trying to find HIV in this infant and no body was able to find any.

“And so we really can quite confidently conclude at this point that the child does very much appear to be cured.”

A spokeswoman for the HIV/Aids charity the Terrence Higgins Trust said: “This is interesting, but the patient will need careful ongoing follow-up for us to understand the long-term implications for her and any potential for other babies born with HIV.”

Source: BBC

Skin patches ‘tackle prostate cancer’.


_66155129_patchtrial0_66153951_m8650167-prostate_cancer,_sem-spl

Skin patches which deliver oestrogen into the blood may be a cheaper and safer treatment for prostate cancer than current therapies, a study says.

The main treatment is injections of a chemical to cut levels of testosterone – the driving force of many prostate cancers – but it causes side effects.

The Imperial College London study in the Lancet Oncology compared patches and injections in 254 patients.

It found patches were safe and should avoid menopause-like side effects.

‘Effective treatments’

Using oestrogen to treat prostate cancer is an old treatment.

Both oestrogen and testosterone are very similar chemically, so ramping up the levels of oestrogen in the body can reduce the amount of testosterone produced – and slow prostate cancer growth.

However, taking oral oestrogen pills caused significant health problems by overdosing the liver. The organ then produced chemicals which caused blood clots, heart attacks and strokes.

The preferred treatment is injections of a drug, LHRHa, which reduces the production of both oestrogen and testosterone. However, this has side effects similar to the menopause in women – resulting in poor bone health and diabetes.

Prof Paul Abel, from Imperial College London, said: “We’re not claiming this is equivalent to current therapies yet, but it does look like we are getting castration levels of testosterone.”

However, the researchers need to follow patients for longer.

“The next step is to test if the oestrogen patches are as effective at stopping the growth of prostate cancer as the current hormone treatments, we’re now testing this in over 600 patients.”

Kate Law, from the charity Cancer Research UK which part funded the study, said: “More men than ever are surviving prostate cancer thanks to advances in research, but we still urgently need to find more effective treatments and reduce side effects.

“This trial is an important step towards better and kinder treatments that could bring big benefits to men with prostate cancer in the future.”

Dr Iain Frame, director of research at Prostate Cancer UK, said: “It is unclear as yet if hormone patches could be an effective alternative to hormone injections, but we await with anticipation the results of the further trials planned which could in time offer men hope for the future.”

Source: BBC